ES2159764T3 - 5-azabiciclo(3.1.0)hexilalquil-2-piperidonas y -glutarimidas como antagonistas de receptores de neurocininas. - Google Patents

5-azabiciclo(3.1.0)hexilalquil-2-piperidonas y -glutarimidas como antagonistas de receptores de neurocininas.

Info

Publication number
ES2159764T3
ES2159764T3 ES96938206T ES96938206T ES2159764T3 ES 2159764 T3 ES2159764 T3 ES 2159764T3 ES 96938206 T ES96938206 T ES 96938206T ES 96938206 T ES96938206 T ES 96938206T ES 2159764 T3 ES2159764 T3 ES 2159764T3
Authority
ES
Spain
Prior art keywords
rent
cicloalquilo
arilo
group
neurocinine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96938206T
Other languages
English (en)
Inventor
Alexander Roderick Mackenzie
Allan Patrick Marchington
Donald Stuart Middleton
Sandra Dora Meadows
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2159764T3 publication Critical patent/ES2159764T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE FORMULA (I) Y SUS SALES, EN DONDE R 1 ES AUN GRUPO C 1 C 6 ALQUILO, C 3 C 7 CICLOALQUILO, C 3 C 7 CICLOALQUILO (C 1 C 4 )ALQUILO, ARILO O ARIL (C 1 C 4 )ALQUILO; EN LOS QUE EL GRUPO C 1 C 6 ALQUILO ES OPCIONALMENTE SUSTITUIDO POR FLUOR Y EL GRUPO C 3 C 7 CICLOALQUILO O C 3 C 7 CICLOALQUILO (C 1 C 4 )ALQUILO ES OPCIONALMENTE SUSTITUIDO EN EL ANILLO CICLOALQUILO POR HASTA DOS SUBSTITUYENTES SELECCIONADOS INDEPENDIENTEMENTE DE HALO, C SUB,1 C 4 ALCOXI O HAL (C 1 C 4 ) ALCOXI; R 2 ES FENIL OPCIONALMENTE SUSTITUIDO CON UNO O DOS SUBSTITUYENTES HALO O ES INDOLILO, TIENILO, BENZOTIENILO O NAFTILO; R 3 ES NH 2 , -NR 4 SO 2 (C 1 C 6 ALQUILO), -NR 4 SO 2 ARILO, NR 4 SO 2 N(R 4 ) 2, -NR 4 CO (C 1 C 6 ALQUILO), -NR 4 CO ARILO O UN GRUPO O FORMULA (A) EN LA QUE W ES O, NR 5 , CH(OH), CHCO 2 H, CHN(R 4 ) 2 , CHF, CF 2 , C = O O CH2 ; R 4 ES H O C 1 C 6 ALQUILO; R 5 ES H, C 1 C 6 ALQUILO, C 3 C 7 CICLOALQUILO , C 3 C 7 CICLOALQUILO (C 1 C 6 )ALQUILO, C2 C 6 ALCANOILO, C 4 C 8 CICLOALCANOILO, C 3 C 7 CICLOALQUILO (C 2 C 6 )ALCANOILO, ARILO CO, C 1 C 6 ALQUILO SO 2 -, (R 4 2 NSO 2 -, C 3 C 7 CICLOALQUILO SO 2 -, C SUB,3 C 7 CICLOALQUILO(C 1 C 6 )ALQUILO SO 2 O ARILO SO 2 ; X ES CH 2 O C = =; M ES 0, 1 O 2 CON TAL QUE M NO SEA O SI W ES NR 5 , C = O, O O; Y N ES UN NUM ERO ENTERO DE 1 A 4. ESTOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES DE LA NEUROCININA UTILES EN EL TRATAMIENTO DE VARIOS TRASTORNOS MEDICOS, INCLUIDA LA INCONTINENCIA URINARIA, EL ASMA Y TRASTORNOS RELACIONADOS.
ES96938206T 1995-11-25 1996-11-11 5-azabiciclo(3.1.0)hexilalquil-2-piperidonas y -glutarimidas como antagonistas de receptores de neurocininas. Expired - Lifetime ES2159764T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9524157.6A GB9524157D0 (en) 1995-11-25 1995-11-25 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2159764T3 true ES2159764T3 (es) 2001-10-16

Family

ID=10784466

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96938206T Expired - Lifetime ES2159764T3 (es) 1995-11-25 1996-11-11 5-azabiciclo(3.1.0)hexilalquil-2-piperidonas y -glutarimidas como antagonistas de receptores de neurocininas.

Country Status (13)

Country Link
US (1) US6034082A (es)
EP (1) EP0862567B1 (es)
JP (1) JP2978566B2 (es)
AT (1) ATE203747T1 (es)
CA (1) CA2230936C (es)
DE (1) DE69614270T2 (es)
DK (1) DK0862567T3 (es)
ES (1) ES2159764T3 (es)
GB (1) GB9524157D0 (es)
GR (1) GR3036688T3 (es)
MX (1) MX9804105A (es)
PT (1) PT862567E (es)
WO (1) WO1997019942A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812037D0 (en) * 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
AU7334901A (en) 2000-07-11 2002-01-21 Du Pont Pharm Co Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
AU2003223010A1 (en) * 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0513359A (pt) 2004-07-15 2008-05-06 Amr Technology Inc tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
US20100105688A1 (en) 2007-01-24 2010-04-29 Glaxo Group Limited Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
EP2429296B1 (en) 2009-05-12 2017-12-27 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
AU2010307198B9 (en) 2009-10-14 2014-02-13 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
JP2013542929A (ja) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド 新規ビシクロ環化合物
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
ES2707305T3 (es) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de HDM2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
MY197850A (en) * 2017-09-07 2023-07-20 Chemimmune Therapeutics Llc Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
KR20220053557A (ko) 2019-07-17 2022-04-29 2692372 온타리오 인크. 벤젠술폰아미드 유도체 및 그의 용도
WO2021099842A1 (en) * 2019-11-22 2021-05-27 2692372 Ontario Inc. Pentafluorobenzenesulfonamide derivatives and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams

Also Published As

Publication number Publication date
EP0862567B1 (en) 2001-08-01
WO1997019942A1 (en) 1997-06-05
GB9524157D0 (en) 1996-01-24
EP0862567A1 (en) 1998-09-09
ATE203747T1 (de) 2001-08-15
CA2230936C (en) 2001-09-11
MX9804105A (es) 1998-09-30
DK0862567T3 (da) 2001-10-08
US6034082A (en) 2000-03-07
GR3036688T3 (en) 2001-12-31
PT862567E (pt) 2001-11-30
CA2230936A1 (en) 1997-06-05
JPH10512598A (ja) 1998-12-02
JP2978566B2 (ja) 1999-11-15
DE69614270T2 (de) 2001-11-15
DE69614270D1 (de) 2001-09-06

Similar Documents

Publication Publication Date Title
ES2159764T3 (es) 5-azabiciclo(3.1.0)hexilalquil-2-piperidonas y -glutarimidas como antagonistas de receptores de neurocininas.
AR002012A1 (es) Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
ATE61045T1 (de) Sulfoniumsalze mit saeurelabilen gruppierungen.
ES2100187T3 (es) Derivados de carboestirilos y composiciones farmaceuticas que los contienen.
EA200000391A1 (ru) Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
PT97254A (pt) Processo para a preparacao de azoles substituido e de composicoes farmaceuticas que os contem
ES2153364T3 (es) Antimicoticos de tetrahidrofurano tri-sustituido.
ATE132156T1 (de) Latente carbamat-silizium-haftvermittler und verfahren zu deren herstellung und verwendung
ES2032749T3 (es) Acidos oxoftalazinil-aceticos heterociclicos.
DK0773956T3 (da) Renset form for streptograminer, fremstilling deraf og farmaceutiske sammensætninger, der indeholder denne
DK385679A (da) Fremgangsmaade til fremstilling af immunomodulatorer og virumodvirkende midler
BR8907156A (pt) Composicao liquida e processo para obter uma composicao liquida
ATE550331T1 (de) Glycosidasehemmer und verfahren zu dessen herstellung
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
ES2064729T3 (es) Complejos de rutenio (iii) como agentes antineoplasticos.
ES2069841T3 (es) Nuevos derivados de imidazo-(1,2-c)-quinazolina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE69132689D1 (de) Biologisch aktive amine
ES2152237T3 (es) Pirazolo(4,3-c)piridinas, un procedimiento para su preparacion y su uso como inhibidores de la recaptacion de serotonina.
ATE56434T1 (de) Indolinonderivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung.
ES2112483T3 (es) 4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa.
ES2038740T3 (es) Procedimiento de obtencion de compuesos guanidicos que comprenden un ion tetrafenilborato sustituido.
ES8801662A1 (es) Un procedimiento para preparar derivados de acido 1-destia-2-tiacefalosporanico.
DE3767132D1 (de) Polyfluorierte verbindungen und verfahren zu deren herstellung.
ES2056811T3 (es) Derivados de cinolina, procedimiento para su preparacion y composiciones herbicidas que los contienen.
ES2155546T3 (es) Bencenosulfonil-ureas y -tioureas sustituidas, procedimiento para su preparacion y el uso de preparaciones farmaceuticas basadas en estos compuestos, asi como medicamentos que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 862567

Country of ref document: ES